189 related articles for article (PubMed ID: 34917499)
1. Gustave Roussy Immune Score as a Novel Prognostic Scoring System for Colorectal Cancer Patients: A Propensity Score Matching Analysis.
Tian S; Cao Y; Duan Y; Liu Q; Peng P
Front Oncol; 2021; 11():737283. PubMed ID: 34917499
[TBL] [Abstract][Full Text] [Related]
2. Gustave Roussy Immune Score based on a three-category risk assessment scale serves as a novel and effective prognostic indicator for surgically resectable early-stage non-small-cell lung cancer: A propensity score matching retrospective cohort study.
Li SJ; Zhao L; Wang HY; Zhou HN; Ju J; Du H; Che GW
Int J Surg; 2020 Dec; 84():25-40. PubMed ID: 33086147
[TBL] [Abstract][Full Text] [Related]
3. Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study.
Shangguan J; Huang X; Liu X; Zhang Z; Zhang X; Yu J; Chen D
Front Oncol; 2023; 13():1195499. PubMed ID: 37205200
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the Naples prognostic score in colorectal cancer patients undergoing curative resection: a propensity score matching analysis.
Sugimoto A; Fukuoka T; Shibutani M; Kasashima H; Kitayama K; Ohira M; Maeda K
BMC Gastroenterol; 2023 Mar; 23(1):88. PubMed ID: 36966294
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score.
Li Y; Pan Y; Lin X; Hou J; Hu Z; Xu L; Zhou Z; Zhang Y; Chen M; Hu D
Front Pharmacol; 2021; 12():819985. PubMed ID: 35237150
[No Abstract] [Full Text] [Related]
6. Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):55-61. PubMed ID: 30834052
[TBL] [Abstract][Full Text] [Related]
7. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
Minami S; Ihara S; Ikuta S; Komuta K
World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
[TBL] [Abstract][Full Text] [Related]
8. Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer.
Jiang H; Li B; Wu M; Wang Q; Li Y
BMC Cancer; 2024 Apr; 24(1):428. PubMed ID: 38589844
[TBL] [Abstract][Full Text] [Related]
9. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer.
Minami S; Ihara S; Komuta K
World J Oncol; 2020 Jun; 11(3):98-105. PubMed ID: 32494316
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma.
Basoglu T; Babacan NA; Ozturk FE; Arikan R; Demircan NC; Telli TA; Ercelep O; Dane F; Yumuk PF
Indian J Cancer; 2023; 60(2):179-184. PubMed ID: 36861712
[TBL] [Abstract][Full Text] [Related]
11. Gustave Roussy Immune Score (GRIm-Score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma.
Feng JF; Wang L; Yang X; Chen S
J Cancer; 2020; 11(6):1334-1340. PubMed ID: 32047540
[No Abstract] [Full Text] [Related]
12. Gustave Roussy Immune Score (GRIm-Score) as a Prognostic and Predictive Score in Metastatic Colorectal Cancer.
Cotan H; Iaciu C; Radu E; Niculae T; Rosu OA; Nitipir C
Cureus; 2024 Apr; 16(4):e58935. PubMed ID: 38800241
[TBL] [Abstract][Full Text] [Related]
13. The Relationship Between Preoperative Systemic Immune Inflammation Index and Prognostic Nutritional Index and the Prognosis of Patients With Alveolar Hydatid Disease.
Ren B; Chen X; Lei P; Hou L; Wang H; Zhou Y; Ren L; Fan H; Wang Z; Yuan J
Front Immunol; 2021; 12():691364. PubMed ID: 34248983
[TBL] [Abstract][Full Text] [Related]
14. Predictive values of the hemoglobin, albumin, lymphocyte and platelet score (HALP) and the modified -Gustave Roussy immune score for esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy.
Shi Y; Shen G; Zeng Y; Ju M; Chen X; He C; Liang L; Ge X; Sun X; Di X
Int Immunopharmacol; 2023 Oct; 123():110773. PubMed ID: 37562292
[TBL] [Abstract][Full Text] [Related]
15. Creation of a Novel Inflammation-Based Score for Operable Colorectal Cancer Patients.
Huang Q; Cao Y; Wang S; Zhu R
J Inflamm Res; 2020; 13():659-671. PubMed ID: 33116746
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the Gustave Roussy immune (GRIm) score in cancer patients: a meta-analysis.
Sun KX; Xu RQ; Rong H; Pang HY; Xiang TX
Ann Med; 2023; 55(2):2236640. PubMed ID: 37851510
[TBL] [Abstract][Full Text] [Related]
17. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
18. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.
Lenci E; Cantini L; Pecci F; Cognigni V; Agostinelli V; Mentrasti G; Lupi A; Ranallo N; Paoloni F; Rinaldi S; Nicolardi L; Caglio A; Aerts S; Cortellini A; Ficorella C; Chiari R; Di Maio M; Dingemans AC; Aerts JGJV; Berardi R
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801320
[TBL] [Abstract][Full Text] [Related]
19. Naples Prognostic Score as a novel prognostic prediction tool in video-assisted thoracoscopic surgery for early-stage lung cancer: a propensity score matching study.
Li S; Wang H; Yang Z; Zhao L; Lv W; Du H; Che G; Liu L
Surg Endosc; 2021 Jul; 35(7):3679-3697. PubMed ID: 32748268
[TBL] [Abstract][Full Text] [Related]
20. The Role of Cancer-Elicited Inflammatory Biomarkers in Predicting Early Recurrence Within Stage II-III Colorectal Cancer Patients After Curable Resection.
Ying HQ; Liao YC; Sun F; Peng HX; Cheng XX
J Inflamm Res; 2021; 14():115-129. PubMed ID: 33500648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
